GHK-Cu applied topically has moderate human evidence (Lorentic 2012, n=71 RCT). Ipamorelin's only peer-reviewed human evidence is acute GH secretion in healthy volunteers (Raun 1998, PMID 9783708). There are zero published human RCTs for Ipamorelin + body composition / anti-aging outcomes, and zero for GHK-Cu injectable use. The two peptides act on orthogonal mechanisms — GH-axis vs. collagen/fibroblast signaling — and they are not WADA-equivalent.
Topical GHK-Cu has moderate human evidence. Ipamorelin's only human evidence is acute GH secretion. The popular use cases (body composition, anti-aging, systemic longevity) have zero published human RCTs for Ipamorelin, and injectable GHK-Cu has zero published human RCTs. This page synthesizes the existing Ipamorelin deep-dive and GHK-Cu deep-dive into a single scannable reference. It does not introduce new evidence.
Each row states a claim that is supported by a specific peer-reviewed citation. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).
| Claim | Ipamorelin evidence | GHK-Cu evidence |
|---|---|---|
| Plausible human mechanism | Established in humansSelective ghrelin-receptor (GHSR-1a) agonism, pulsatile GH release with minimal cortisol/prolactin stimulation. Raun K, et al. Endocrinology. 1998;139(11):5483. PMID: 9783708 | Mechanism + targeted topical human dataCollagen I/III + elastin upregulation in fibroblasts; angiogenic and anti-inflammatory cytokine modulation. Originally isolated from human plasma by Pickart in 1973; mechanism replicated across multiple in vitro and topical studies described in the GHK-Cu research summary. |
| Skin / collagen outcome (topical) | NoneNo human RCT for skin or collagen endpoints. Mechanism operates through GH, not topical fibroblast signaling. | Moderate (topical)Lorentic et al. 2012 (n=71, double-blind RCT, Archives of Dermatological Research) supports topical GHK-Cu for skin elasticity / collagen density. Draelos et al. 2006 (J Cosmet Dermatol) supports topical GHK-Cu eye-cream outcomes. |
| Hair restoration | NoneNo human RCT. Not a documented indication for Ipamorelin. | LimitedLimited human data and mechanistic data from the studies catalogued in /peptide/ghk-cu. Not a primary documented indication. |
| Body composition / fat loss / muscle | None (mechanism only)Raun 1998 establishes acute GH release but did not measure body-composition outcomes. No human RCT for muscle gain or fat loss; mechanism-only extrapolation. | NoneGHK-Cu's mechanism is collagen/fibroblast, not anabolic. No human RCT for body composition. |
| Anti-aging / longevity (systemic) | NoneNo human RCT. Mechanism-only extrapolation from the GH/IGF-1 axis; the GH-rise-then-meaningful-clinical-change step is untested in humans. | Moderate topical; none injectableLorentic 2012 supports topical skin-aging outcomes. "Anti-aging" in the injectable sense has zero published human RCTs. |
| Human RCT (any indication) | None published (one GI Phase II)Novo Nordisk NNC 26-0161 programme: post-operative ileus Phase II trials, late 1990s, results not published in peer-reviewed journals. | Topical RCTs exist; injectable has noneTopical RCTs: Lorentic 2012, Draelos 2006. Injectable GHK-Cu: no published human RCT. |
| WADA status | Prohibited (S2 — GH-releasing peptides, at all times) | Not listed |
| FDA status | Not approved; Novo Nordisk programme shelved before NDA | Cosmetic / GRAS topical; no injectable approval |
Citations reused from the Ipamorelin deep-dive, GHK-Cu deep-dive, and GHK-Cu research summary. No new PMIDs introduced — the underlying studies are the same ones reviewed on those pages.
Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them for the popular endpoints.
Three honest verdicts. The framing mirrors the evidence-gap language used across the underlying deep-dives — choosing one peptide over another does not establish human efficacy for either, it only frames where the different mechanistic stories have the strongest backing.
Ipamorelin's only peer-reviewed human evidence is acute GH secretion in healthy volunteers (Raun 1998, PMID: 9783708), with minimal cortisol/prolactin cross-talk. This is a real, replicated pharmacodynamic finding. Caveats: the popular use cases — body composition, anti-aging, recovery — have no human RCT. WADA S2 prohibits Ipamorelin at all times for athletes subject to testing. The Novo Nordisk Phase III programme did not proceed, and the compound is not FDA-approved for any indication.
The strongest human evidence for GHK-Cu is topical and cosmetic: the Lorentic 2012 RCT (n=71, Archives of Dermatological Research) and the Draelos 2006 study (J Cosmet Dermatol) both test topical serum. These are legitimate, replicated anti-aging outcomes — visible, measurable skin elasticity and collagen density improvements. Caveats: "GHK-Cu injectable" is a separate question with no published human RCT. The online claim that topical efficacy implies injectable efficacy is mechanism-only and unsupported.
Unlike recovery-area peptides (e.g. BPC-157 + TB-500, which share nearby mechanisms), Ipamorelin and topical GHK-Cu act on genuinely distinct biological systems. The combination is theoretically rational in a way that BPC-157 + TB-500 is not — different rate-limiting steps in different pathways. Caveats: there is no published study of the combination in humans for any use case. Athletes using Ipamorelin face WADA S2 exposure regardless of the topical GHK-Cu component. The combination's risk profile is unknown.
"Evidence tier" and "delivery method" are the two fields most often conflated in this comparison. Four specific confusions to watch for:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (WADA S2 vs. not listed): Ipamorelin is WADA S2 prohibited at all times — in-competition and out-of-competition. A positive test is a full anti-doping rule violation; there is no Therapeutic Use Exemption (TUE) pathway for GHRPs. Topical GHK-Cu, in contrast, is not on the WADA prohibited list — athletes can use a cosmetic GHK-Cu topical without prohibition. The two peptides are not WADA-equivalent.
Anyone seeking an FDA-approved therapy: neither is approved for any indication. Ipamorelin's Novo Nordisk programme (NNC 26-0161) was shelved before NDA. GHK-Cu is cosmetic / GRAS topical only with no injectable approval; injectable GHK-Cu sits outside any approved regulatory pathway.
Anyone needing proven human efficacy for body composition, anti-aging, or systemic longevity: zero published human RCTs exist for Ipamorelin + any of these endpoints; zero published human RCTs exist for GHK-Cu injectable (only Lorentic 2012 supports topical skin). If you need a therapy with validated human efficacy for these outcomes, neither peptide is the right starting point.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.